the effect of emdogain on peri-implant mucosal inflammation (PIMI)

The effect of Emdogain application on non-surgical management of peri-implant mucosal inflammation (PIMI) and its Cytokine profile: a double blind randomised clinical trial of efficacy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013060113543N1

Enrollment

Registered

2013-09-11

Start date

2013-09-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peri-implamtitis(complications of dental implant). Infection and inflammatory reaction due to other internal prosthetic devices, implants and grafts

Interventions

In-Office Protocol 1 (control group): Debride subgingival environment including threads meticulously using ultrasonic instrument. In-Office Protocol 2(test group):The non-surgical application of emdo

Treatment - Drugs

In-Office Protocol 1 (control group): Debride subgingival environment including threads meticulously using ultrasonic instrument. In-Office Protocol 2(test group):The non-surgical application of emd

Eligibility

Sex/Gender

All

Age

18 Years to 149 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Adults aged 18 or over years; PIMI with Implant Success Index (ISI) III,IV (according to KadkhodazadehM, Amid R classification ) defined as presence of BOP, without soft tissue recession with radiographic bone loss = 2mm, Pocket depth=4mm ; Implant in function for = 1 year Exclusion criteria: Uncontrolled systemic diseases; Smoking; Active periodontal disease; Pregnancy and lactation; Radiation therapy; Drug and alcohol abuse; Consumption of systemic antibiotics in the late 1 month; Long-term use of any drug affects periodontal tissue conditions (e.g. non-steroidal anti-inflammatory drugs, anti-consultants, calcium channel blockers,bisphosphonates,...); Treatment intervention for PIMI in the late 3 months; Need for bacterial prophylaxis with systemic antibiotics; Infectios disease such as AIDS, hepatitis, and tuberculosis

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
BOP. Timepoint: 0,2,4,14 week. Method of measurement: probe.	—

Secondary

Measure	Time frame
Pocket depth. Timepoint: 0,2,4,14w. Method of measurement: probe.;IL-6 , IL-17. Timepoint: 0,2,4,14 WEEK. Method of measurement: ELISA.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Moradi Abozar

Faculty of Dentistry,Tabriz University of Medical Sciences

dr_amk15@yah00.com+98 41 1335 5964

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026